These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1158 related articles for article (PubMed ID: 28895416)

  • 1. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
    Caglar M; Yener C; Karabulut E
    Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of
    Han N; Sun X; Qin C; Hassan Bakari K; Wu Z; Zhang Y; Lan X
    AJR Am J Roentgenol; 2018 May; 210(5):1155-1163. PubMed ID: 29629798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.
    Khan K; Athauda A; Aitken K; Cunningham D; Watkins D; Starling N; Cook GJ; Kalaitzaki E; Chau I; Rao S
    Oncologist; 2016 Dec; 21(12):1502-1508. PubMed ID: 27742904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI.
    Stojiljkovic M; Sobic Saranovic D; Odalovic S; Popovic M; Petrovic J; Rankovic N; Veljkovic M; Artiko V
    Radiol Oncol; 2022 Dec; 56(4):453-460. PubMed ID: 36317553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
    Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application and Indication of Carcinoembryonic Antigen Triggered 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Detection of Relapse of Colorectal Cancer Patients After Curative Therapy.
    Yu X; Zhu L; Dai D; Song X; Chen W; Zhu Y; Li X; Xu W
    J Comput Assist Tomogr; 2017; 41(5):719-725. PubMed ID: 28481810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
    Panagiotidis E; Datseris IE; Exarhos D; Skilakaki M; Skoura E; Bamias A
    Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of ¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations.
    Zhang Y; Feng B; Zhang GL; Hu M; Fu Z; Zhao F; Zhang XL; Kong L; Yu JM
    World J Gastroenterol; 2014 Jun; 20(21):6608-14. PubMed ID: 24914384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.